Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MeiraGTx, LLC
Individual participation in this study will last approximately 48 months for participants who received AAV2-hAQP1 in Study MGT-AQP1-201 and at least 60 months for participants who receive AAV2-hAQP1 in Study MGT-AQP1-202.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Received study drug in Study MGT-AQP1-201
You may not be if
Withdrew consent to participate in Study MGT-AQP1-201.
Clareo Health | Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
